(MedPage Today) — CHICAGO — Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) compared with FLOT alone in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115836
Author :
Publish date : 2025-06-01 12:00:00
Copyright for syndicated content belongs to the linked Source.
